BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Market News

Honeywell elevates Building Automation chief to lead Process Technology as Ken West departs

Moe Alsumidaie by Moe Alsumidaie
August 20, 2026
in Market News
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

Honeywell Technologies announced a leadership reshuffle on Aug. 19, 2026, promoting Billal Hammoud from President and CEO of Building Automation to the same role at Process Technology, effective Oct. 1, with Juan Picon, formerly President of Building Automation Americas, succeeding him. Ken West, the outgoing Process Technology leader, is departing the company. The moves matter because they place the executive who accelerated Building Automation’s organic growth from 2% to 8% in charge of a larger, more complex segment within the Process Automation and Technology reportable business, signaling confidence in Hammoud’s operational playbook while testing whether his methods translate beyond the building sector.

Under Hammoud’s three-year tenure at Building Automation starting in 2023, the business achieved 8% organic sales growth in 2025, up from 2% in 2023, and delivered seven consecutive quarters of high-single-digit organic growth with margin expansion. The company attributes this acceleration to a sharper focus on higher-growth verticals such as healthcare, hospitality and data centers, a regional structure empowering local teams, and new product innovation including Honeywell Forge Connected Buildings. Picon, who rejoined Honeywell in 2024 after external roles at Sensata Technologies and WESCO Distribution, brings more than two decades of prior Honeywell experience and earned the company’s 2025 Chairman’s Award. The announcement contains no forward guidance, earnings revision, or quantified targets for either successor’s new role.

What it means

The promotion reflects Hammoud’s proven ability to reaccelerate a mature business through vertical segmentation and digital product adoption. Building Automation’s 8% organic growth in 2025 stands out against Honeywell’s reported FY2025 revenue decline of 74.7%, suggesting the business benefited from either portfolio actions (divestitures or acquisitions) or genuine operational momentum. The reconciliation table confirms that 5 percentage points of Building Automation’s 13% reported sales growth came from acquisitions, meaning organic growth of 8% was achieved on a smaller revenue base after stripping out M&A and currency effects. This is material: Hammoud inherited a 2% organic growth business and doubled its rate in three years without relying on acquisition-driven top-line expansion.

Process Technology, by contrast, is described as part of the larger Process Automation and Technology segment and includes the $4.95 billion Access Solutions acquisition Hammoud helped integrate. The company frames his move as a natural progression, citing his “track record of driving operational rigor to deliver strong results and successful M&A integration.” The unspoken test is whether the vertical-market and regional-empowerment playbook that worked in building controls, a sector with clear end-user verticals like healthcare and hospitality, translates to process automation, which serves chemical, refining, and manufacturing customers with different buying cycles and technical requirements.

BullScope TerminalHONEYWELL INTERNATIONAL INC was the article. The engine is the product.Same yardsticks, any ticker: filed financials in, math-vs-mood out. Nothing here is advice; it is the evidence, organized.Run another company →

Picon’s appointment to Building Automation introduces execution risk. He has been in the role of Building Automation Americas President for less than a year and is being promoted to global CEO of a business that just achieved its strongest growth trajectory. The company notes his “measurable business impact” and regional restructuring work, but does not quantify results or provide forward guidance for Building Automation under his leadership. The honest open question is whether Building Automation’s 8% organic growth rate was driven by Hammoud’s strategic choices (verticals, products, structure) or by favorable market conditions and the Access Solutions integration tailwinds that may not persist.

What to watch

Honeywell’s next quarterly earnings release will be the first opportunity to assess whether Building Automation’s organic growth momentum continues under Picon, and whether Process Technology shows any acceleration or margin improvement under Hammoud’s leadership. Any guidance revision or commentary on these segments’ forward outlook will clarify whether management views these moves as confidence-building or as a reset of expectations.

Source: the company’s 8-K filed 2026-08-19 with the SEC.

BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read HONEYWELL INTERNATIONAL INC’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Procter & Gamble accelerates organic sales growth to 4% as pricing and volume both contribute

by Moe Alsumidaie
October 23, 2026
0

Procter & Gamble's first quarter of fiscal 2027 delivered organic sales growth of 4 percent, up from the prior year's 3.3 percent, driven b

Read moreDetails

Abbott to split Nutrition into independent company with $8.5 billion in sales by end of 2027

by Moe Alsumidaie
October 22, 2026
0

Abbott announced plans to separate its Nutrition business into a standalone publicly traded company by the end of 2027, creating a $8.5 bil

Read moreDetails

GE Aerospace raises 2026 guidance as commercial services orders surge 58 percent

by Moe Alsumidaie
October 21, 2026
0

GE Aerospace lifted full-year profit and cash flow targets after third-quarter orders jumped 58 percent, driven by a backlog of over $170 b

Read moreDetails

Biohaven licenses Japan and Asia rights to Graves’ disease candidate for $80 million upfront and 20% royalties

by Moe Alsumidaie
October 19, 2026
0

Biohaven has licensed its lead extracellular IgG degrader, BHV-1300, to Ono Pharmaceutical for exclusive development and commercialization

Read moreDetails

UnitedHealth’s operating margin surges as medical cost discipline offsets revenue decline

by Moe Alsumidaie
October 15, 2026
0

UnitedHealth Group raised full-year earnings guidance to at least $20.50 per share after third-quarter operating earnings jumped 53 percent

Read moreDetails
Next Post

Amgen: A Bone-Drug Empire Is Shrinking While a Weight-Loss Bet Grows

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Procter & Gamble accelerates organic sales growth to 4% as pricing and volume both contribute

October 23, 2026

Hiring Slowed, Prices Cooled, and the Fed Held Steady: What June’s Numbers Mean for Earnings Season

August 18, 2026

PepsiCo: The Stock Is Priced for Doubt. The Filing Tells a Different Story.

September 22, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.